“This is great news for our team here in Ontario,” said Beleave CEO, Andrew Wnek. “OCS has been diligent and thorough in their application and approval processes. Our selection as an official supplier is further evidence of our best-in-class products and responsible leadership. This adds to our extensive distribution network which already includes British Columbia, Manitoba, and Saskatchewan.”
The Company worked closely with the OCS to finalize an agreement that provides its cannabis at a competitive price, while not compromising on the quality and standards for which Beleave is highly-regarded.
Beleave will package and sell three strains of its cannabis products under the Seven Oaks brand at launch and will continue to expand options for consumers as new varieties become available. The brand is guided by the principles of responsible and safe access to recreational cannabis for adults who like to maintain productive and active lifestyles.
With nearly forty percent of the Canadian population, Ontario represents the largest market for distribution and sales of medical and recreational cannabis in Canada. Beleave already operates a network of medical cannabis clinics in Ontario under the Medi-Green banner. “We will be expanding that network with new locations this fall and anticipate a more aggressive strategy as we approach Spring 2019,” added Wnek.
Beleave applauds the OCS for recognizing its high-quality products and including it on the official suppliers list. The Company looks forward to working with them in the future to ensure professional and responsible access for Ontarioresidents.
ABOUT BELEAVE INC.
Beleave is a biotech company who’s wholly-owned subsidiary Beleave Kannabis Corp. is licensed to cultivate and sell medical cannabis and produce cannabis oils and extracts pursuant to Health Canada’s Access to Cannabis for Medical Purpose Relations. Beleave has developed a network of medical cannabis clinics under the Medi-Green banner and has applied for various patents to broaden its strong research focused foundation.
This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
For further information: Investor Relations Contact: Richard Oyelowo, Phone : (416) 712 – 9402, Email : email@example.com; Media Relations Contact : Grant McLeod, SVP, Regulatory Affairs and General Counsel, Phone : (416) 910 – 3401, Email : firstname.lastname@example.org